MyFinsight
Home
Blog
About
Investments
$6,954,476
(13.60%↑ Y/Y)
Cash and cash
equivalents
$3,845,606
(130.48%↑ Y/Y)
Prepaid expenses and
other current assets
$836,146
(21.37%↑ Y/Y)
Total current assets
$11,636,228
(37.23%↑ Y/Y)
Intangible assets, net
$333,334
(-23.08%↓ Y/Y)
Total assets
$11,969,562
(34.30%↑ Y/Y)
Total liabilities and
shareholders' equity
$11,969,562
(34.30%↑ Y/Y)
Total liabilities
$8,036,891
(26.34%↑ Y/Y)
Total shareholders'
equity
$3,932,671
(54.14%↑ Y/Y)
Accumulated deficit
-$81,339,224
(-29.78%↓ Y/Y)
Accumulated other
comprehensive loss
-$582
Total current
liabilities
$6,613,158
(52.46%↑ Y/Y)
Due to officers -
long term
$1,423,733
(-29.65%↓ Y/Y)
Additional paid in capital
$85,272,477
(30.74%↑ Y/Y)
Accounts payable
$3,109,517
(255.91%↑ Y/Y)
Accrued expenses
$1,757,390
(2.32%↑ Y/Y)
Accrued interest and
financing expense
$1,146,251
(0.00%↑ Y/Y)
Due to officers -
short term
$600,000
(200.00%↑ Y/Y)
Back
Back
Balance Sheet
Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX)
source: myfinsight.com